Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
FSHβ-Melphalan Conjugates
Product Overview
Development Status:
Inactive
Target:
Male
Mode:
Non-hormonal
Delivery Type:
Injectable
Duration Type:
Permanent
Description:
Single dose method of non-surgical male sterilization, administered by injection, which has an effect on murine spermatogenesis. Effect is not permanent, so no further development was pursued.
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
Malphalan
Potential Multi-Purpose Technology (MPT):
No
Regimen:
Single-dose injection
Duration:
Intended to be permanent, but was reversible on testing
Partner:
University of Washington
,
Focused Scientific
Status
Project Phase:
Early Development
Project Stage:
Pre-clinical
Status Details:
Was intended to be a method of permanent sterilization, but effect was not permanent, so no further development was pursued.
Programmatic Considerations
Considerations:
Use of FSHβ as a targeting vector to the testes may permit use of lower dose of melphalan and so reduce potential side effects.
Low-cost technology using available compounds, likely to be inexpensive.
Potential for testicular toxicity such as hypogonadism and/or late testicular neoplasms from the melphalan.
Additional Information
Download Product Report
